Over 30 years of elaborate experience in LDL apheresis: An effective and well-tolerated treatment option for specific patient subgroups

2020 ◽  
Vol 315 ◽  
pp. e26
Author(s):  
A.T. Ull ◽  
E. Waldmann ◽  
I. Riks ◽  
K.G. Parhofer
Keyword(s):  
Treatment Option ◽  
Ldl Apheresis ◽  
Specific Patient ◽  
Patient Subgroups

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial

2015 ◽  
Vol 9 (1) ◽  
pp. 65-71 ◽  
Author(s):  
Eliot A. Brinton ◽  
Uma Kher ◽  
Sukrut Shah ◽  
Christopher P. Cannon ◽  
Michael Davidson ◽  
...  
Keyword(s):  
Plasma Lipids ◽  
Specific Patient ◽  
Cetp Inhibition ◽  
Patient Subgroups

Novel Antipsychotics and Patient Care in State Hospitals

1998 ◽  
Vol 32 (9) ◽  
pp. 906-914 ◽  
Author(s):  
Peter F Buckley
Keyword(s):  
State Hospital ◽  
Cost Savings ◽  
Preliminary Evidence ◽  
The State ◽  
New Agents ◽  
Hospital System ◽  
Specific Patient ◽  
State Hospitals ◽  
Additional Information ◽  
Patient Subgroups

OBJECTIVE: To review and highlight the opportunities and challenges of pharmacologic advances in the use of antipsychotics for the state hospital system. METHODS: A critical review was performed of studies published either as articles or abstracts, on the use of novel antipsychotics, particularly as they relate to the patient population within the state mental hospital system. FINDINGS: The recent availability of new antipsychotic medications within state facilities has resulted in more progressive treatment, reduced recidivism (and consequently cost savings), and preliminary evidence of preferential and superior treatment response in specific patient subgroups (e.g., those with aggression). At the same time, inpatient pharmacy budget increases and uncertainty in guiding the use of novel antipsychotics have influenced the availability of these agents in state hospitals. CONCLUSIONS: State hospital services have, by and large, embraced the developments in pharmacotherapy of schizophrenia. Optimal use of these new agents in this population requires additional information on their relative efficacy in specific patient subgroups.

Can Previous First-Line Therapies for Neisseria gonorrhoeae Be Targeted to Specific Patient Subgroups to Treat Gonorrhea?

2015 ◽  
Vol 42 (1) ◽  
pp. 37-42 ◽  
Author(s):  
Katy Town ◽  
Catherine M. Lowndes ◽  
Gwenda Hughes ◽  
Chinelo Obi ◽  
Stephanie Chisholm ◽  
...  
Keyword(s):  
Neisseria Gonorrhoeae ◽  
First Line ◽  
Specific Patient ◽  
Patient Subgroups

Clinical Guidelines and Policies: Can they Improve Emergency Department Pain Management?

2005 ◽  
Vol 33 (4) ◽  
pp. 783-790 ◽  
Author(s):  
James Ducharme
Keyword(s):  
Pain Management ◽  
Practice Patterns ◽  
Bone Fractures ◽  
Relevant Information ◽  
Long Bone ◽  
Specific Patient ◽  
Change In Practice ◽  
Prevalence Of Pain ◽  
A Prospective Study ◽  
Patient Subgroups

The prevalence of pain in patients presenting to Emergency Departments (ED) has been well documented by both Cordell and Johnston. Equally well documented has been the apparent failure to adequately control that pain. In 1990 Selbst found that patients with long bone fractures received little analgesia in the ED, and Ngai, et al., showed that the under-treatment of pain continued after discharge. In a prospective study, Ducharme and Barber found that up to one third of patients presented with severe pain and were often unrelieved at discharge. Even though specific patient subgroups appear to be at greater risk, all patients are potential victims of oligoanalgesia - the under-treatment of pain. Despite an ever increasing volume of research about pain in emergency medicine, dissemination of relevant information with widespread change in practice patterns has not been witnessed. Recent studies continue to affirm that pain management in the ED is suboptimal.

Reviewing myocardial silent ischemia: Specific patient subgroups

2008 ◽  
Vol 124 (2) ◽  
pp. 139-148 ◽  
Author(s):  
Theodoros Xanthos ◽  
Konstantinos A. Ekmektzoglou ◽  
Lila Papadimitriou
Keyword(s):  
Silent Ischemia ◽  
Specific Patient ◽  
Patient Subgroups

Diagnostic efficiency of rejection monitoring after heart transplantation with cardiac troponin T is improved in specific patient subgroups

2003 ◽  
Vol 17 (3) ◽  
pp. 284-291 ◽  
Author(s):  
Christian A Gleissner ◽  
Roland Klingenberg ◽  
Winfried Nottmeyer ◽  
Stephan Zipfel ◽  
Falk-Udo Sack ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Cardiac Troponin ◽  
Troponin T ◽  
Cardiac Troponin T ◽  
Diagnostic Efficiency ◽  
Specific Patient ◽  
Patient Subgroups

scholarly journals A Review of the Clinical Outcomes for Patients Diagnosed with Brainstem Metastasis and Treated with Stereotactic Radiosurgery

ISRN Surgery ◽  
2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Andrew F. Lamm ◽  
Ameer L. Elaimy ◽  
Wayne T. Lamoreaux ◽  
Alexander R. Mackay ◽  
Robert K. Fairbanks ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Stereotactic Radiosurgery ◽  
Clinical Outcomes ◽  
Local Control ◽  
Linear Accelerator ◽  
Patient Survival ◽  
Specific Patient ◽  
Comprehensive Review ◽  
Brainstem Lesions ◽  
Patient Subgroups

Only 3%–5% of all brain metastases are located in the brainstem. We present a comprehensive review of the clinical outcomes from modern studies that treated patients with brainstem metastasis using either a Gamma Knife or a linear accelerator-based stereotactic radiosurgery. The median survival time of patients was compared to better understand what clinical or treatment factors are predictive of improved survival. This information can then be utilized to optimize patient care. The data suggests that higher prescribed marginal dose and the associated greater local control of brainstem lesions are associated with longer patient survival. Further research is necessary to better describe the most effective dose for individual brainstem lesions and to tailor optimum therapy to specific patient subgroups.

scholarly journals Integrating subgroups with mixed-type endpoints in early phase oncology trials

2019 ◽  
Vol 29 (2) ◽  
pp. 498-507
Author(s):  
Lili Zhao ◽  
Carl Koschmann
Keyword(s):  
Mixed Type ◽  
Progression Free Survival ◽  
Efficient Estimation ◽  
Specific Patient ◽  
Free Survival ◽  
Borrowing Strength ◽  
Anti Cancer ◽  
Survival Endpoints ◽  
Disease Subtypes ◽  
Patient Subgroups

Testing anti-cancer agents with multiple disease subtypes is challenging and it becomes more complicated when the subgroups have different types of endpoints (such as binary endpoints of tumor response and progression-free survival endpoints). When this occurs, one common approach in oncology is to conduct a series of small screening trials in specific patient subgroups, and these trials are typically run in parallel, independent of each other. However, this approach does not consider the possibility that some of the patient subpopulations respond similarly to therapy. In this article, we developed a simple approach to jointly model subgroups with mixed-type endpoints, which allows borrowing strength across subgroups for efficient estimation of treatment effects.

Sign in / Sign up

Export Citation Format

Share Document